Therma Bright Advances in Growing Compression Therapy Market with Innovative Venowave VW5

Therma Bright Inc. is making significant strides in the compression therapy market with its innovative Venowave VW5, a portable, battery-powered compression device that addresses critical healthcare needs in an aging population.

The company has achieved rapid Medicare and Medicaid reimbursement approvals, securing a HCPCS Level II code within 60 days. Since October 1, 2024, over 110 Venowave VW5 units have been deployed across the United States, with 25 units already receiving full reimbursement through commercial and federal healthcare networks.

The Venowave VW5 offers unique advantages in the medical device landscape. It is a compact, lightweight device weighing just 250 grams, designed to improve vascular and lymphatic flow in lower limbs. Clinical studies demonstrate its effectiveness, showing a 64% increase in venous blood flow within two minutes and an 88% increase after 50 minutes of use.

Strategic partnerships are driving Therma Bright’s market expansion. The company has signed a Letter of Intent with DME Authority, a Nashville-based distributor, which commits to purchasing $6 million worth of Venowave VW5 units in the first six months of 2025. Additionally, Valor Medical Solutions has placed an initial order for 100 units, with plans to increase orders biweekly.

The global compression therapy market presents a significant opportunity, with projections indicating growth from $4.18 billion in 2024 to $6.72 billion by 2033, representing a compound annual growth rate of 7.3%. Therma Bright is well-positioned to capitalize on this expanding market through its innovative technology and strategic approach.

Rob Fia, CEO of Therma Bright, emphasized the company’s potential, stating that the rapid reimbursement processing and increasing patient demand suggest significant revenue growth in 2025 and beyond.

The Venowave VW5 stands out as the only Medicare-approved mobile mechanical compression system under HCPCS code E0683, qualifying for reimbursement under ten medical indications. Its FDA designation as Durable Medical Equipment and its ability to be used across multiple patients further enhance its market appeal.

As healthcare continues to evolve, Therma Bright’s innovative approach to compression therapy represents a promising development in non-invasive medical treatment technologies.

Blockchain Registration, Verification & Enhancement provided by NewsRamp™

This news story relied on a press release distributed by News Direct. Blockchain Registration, Verification & Enhancement provided by NewsRamp™. The source URL for this press release is Therma Bright Advances in Growing Compression Therapy Market with Innovative Venowave VW5.